Cushing syndrome, a rare endocrine disorder caused by abnormally excessive amounts of the hormone cortisol, has a new pharmaceutical treatment to treat cortisol overproduction.
Skylar Jeremias
Advertisement
Skylar is an associate editor for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®, and joined AJMC® in 2020. She is responsible for covering all aspects of the ever-changing global biosimilar industry and produces content that is accessible and informative for all health care stakeholders.
She has a BA in journalism and media studies from Rutgers University. You can connect with Skylar on LinkedIn.
Articles by Skylar Jeremias
The analysis looked at 13 of America’s largest employers, including energy, hospitality, retail, transportation, and finance companies.
Limited data about the effects of psoriasis therapy during pregnancy make it difficult to know which options are possible for pregnant patients and which ones can be harmful, according to a review.
An expert panel discussed the systemic and policy barriers to the uptake of biosimilars.
The results are in line with earlier studies, and the current review found a link with bladder cancer and lung cancer.
Investigators say that inconsistencies in the way rare diseases are defined contribute to misdiagnoses, delayed treatment, and other ills that could be addressed with global standards.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Unexplained Pauses Hit Nearly Half of Monthly-Updated CDC Databases, Raising Transparency Concerns
2
Clinical Trial Data Signal a New Era for Atopic Dermatitis, Melanoma, and Psoriasis
3
ACE Inhibitors Linked to Reduced Mortality in Patients with Idiopathic Pulmonary Fibrosis
4
CRC Becomes Leading Cause of Cancer-Related Death in Younger Adults, Highlighting Prevention Gaps
5
